ebook: High-content analysis and infectious disease
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Bioassays and thin-layer chromatography has been used by scientists to analyse molecules in plant extracts as a fast and cost-effective method for identifying new drug compounds.
Tested on plaque reducing assays, researchers have identified a lead candidate multivalent carbohydrate-binding module for the treatment of COVID-19.
7 May 2020 | By PerkinElmer
High-throughput screening (HTS) cascades have evolved to ensure that high quality hits can be identified from large screening collections.
Tests have shown that LAL assays produced from L. polyphemus in aquaculture often has a higher activity than lyophilised and preserved LAL from commercial kits.
A rise in biotechnology R&D activities is expected to drive the growth of the immuno-oncology assay market, with a CAGR of 10.6 percent.
A series of three new assays to screen for drug compounds or proteins that combat the COVID-19 coronavirus has been developed.
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
High-throughput screening of thousands of compounds has revealed several candidates, including lead compound ebselen, with the potential for treating COVID-19.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
ESHG 2019 Conference Presentation: Using KingFisher™ to increase reproducibility in new applications using challenging samples.
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system to identify pools and clones with higher concentrations of bispecific antibodies. Higher throughput was achieved from the multiple simultaneous measures possible on the Octet system and rapid assay times, such as binding optimisation in only 10 minutes.…
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.